Hims stock dropped sharply Friday after the U.S. Food and Drug Administration said the shortage of widely-used weight-loss ...

Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared ...

The "Hims and Hers" commercial railed against ... Narula explains the findings of a new study on GLP-1 drugs commonly used for weight loss. Dr. Alexandra Sowa, an obesity medicine specialist ...

Direct-to-consumer virtual care company Hims & Hers is the latest digital health company to announce it will add GLP-1 medications to its offerings to assist users with weight-loss management ... and ...

An ad for compounded versions of weight-loss drug semaglutide by telehealth company Hims & Hers has attracted ... of a prescription medicine. GLP-1 agonist semaglutide is the active ingredient ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers Super Bowl commercial “Sick of the System,” aren’t approved by the FDA. © 2025 ...

Cogent Biosciences is expected to close a follow-on public offering today, with proceeds of approximately $225 million that will be used to fund the development of its lead drug bezuclastinib ...

Hims & Hers Health (HIMS) stock falls as the FDA declares that Novo Nordisk's (NVO) weight loss therapies are no longer in ...

Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...

Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...

Yeezy isn’t the only company being called out for its “bait-and-switch” Super Bowl commercial, a Californian company called ...

An analysis by MedPage Today found that in September 2024 there were more than 125,000 prescriptions written for GLP-1 weight-loss drugs by pediatric and adolescent medicine specialists ...